What is GeniPhys?
Based in Zionsville, Indiana, GeniPhys is a pioneering biotechnology enterprise dedicated to the development and commercialization of advanced collagen materials. The company's core competency lies in its ability to support the custom design and fabrication of collagen scaffolds, which are essential for accelerated and improved tissue restoration and regeneration. By providing a versatile platform for medical professionals and researchers, GeniPhys is effectively bridging the gap between laboratory innovation and clinical application.
The company's market position is defined by its focus on high-impact healthcare solutions. As the demand for sophisticated regenerative therapies grows, GeniPhys remains at the forefront of material science, offering solutions that enhance the body's natural healing processes. Their commitment to precision engineering in collagen fabrication distinguishes them as a key player in the evolving landscape of medical technology.
How much funding has GeniPhys raised?
GeniPhys has raised a total of $9M across 2 funding rounds:
Series A
$6M
Private Equity
$3M
Series A (2023): $6M with participation from Pier 70 Ventures and Elevate Ventures
Private Equity (2026): $3M, investors not publicly disclosed
Key Investors in GeniPhys
Pier 70 Ventures
A venture capital firm specializing in impact-driven healthcare technologies, providing capital and mentorship to accelerate high-growth sustainable companies.
Elevate Ventures
An active investment firm focused on Indiana-based innovation, supporting companies from Pre-Seed through Series A stages with strategic guidance and funding.
What's next for GeniPhys?
Looking ahead, the recent capital influx will likely be directed toward scaling manufacturing capabilities and advancing clinical validation programs. As GeniPhys transitions into this new phase of enterprise-level growth, the focus will shift toward broader market penetration and the potential expansion of its product portfolio. The strategic backing received will provide the necessary runway to navigate regulatory milestones and establish deeper partnerships within the healthcare ecosystem.
Investors are closely monitoring the company's progress as it moves to standardize its collagen fabrication processes for wider clinical adoption. With a robust foundation and clear technological advantages, GeniPhys is poised to redefine standards in tissue regeneration, potentially setting a new benchmark for efficacy and patient outcomes in the coming years.
